Compare Ascendis Pharma A/S (ASND) vs Chipotle Mexican Grill, Inc. (CMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Chipotle Mexican Grill, Inc. — how do they compare? Ascendis Pharma A/S trades at $254.89 (market cap $16.67B), while Chipotle Mexican Grill, Inc. trades at $32.65 (market cap $40.49B). The key difference: Chipotle Mexican Grill, Inc. is far larger — about 2.4× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Chipotle Mexican Grill, Inc. nearer its low. Which is the better fit depends on your goals.
| ASND | CMG | |
|---|---|---|
Market Cap | $16.67B | $40.49B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $44.04 |
52-Week Low | $189.74 | $28.17 |
Enterprise Value | $17.04B | $45.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
CMG trades at $32.71, up 1.76% on the day, with a bearish technical signal driven by moving averages. The company reported strong revenue growth to $11.93B in 2025 and has consistently beaten EPS estimates in recent quarters. However, net cash flow turned negative at -$392M due to aggressive financing activities. Recent news highlights a salmonella outbreak linked to jalapeños, creating near-term headwinds.
Wall Street maintains a bullish stance with a $42.17 consensus price target, representing 29% upside, and no sell ratings. Key risks include food safety issues, margin compression, and negative cash flow. The stock's high P/E of 29.63 requires sustained earnings growth to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →
